Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma
| Autor: | Stanley P. L. Leong, Mohammed Kashani-Sabet, Kevin B. Kim, Michael H.K. Nguyen, R.E. Abendroth |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty CT computed tomography scan MCC Merkel cell carcinoma Phases of clinical research Case Report Dermatology Pembrolizumab Malignancy PET positron emission tomography Avelumab 030207 dermatology & venereal diseases 03 medical and health sciences Merkel cell carcinoma 0302 clinical medicine Internal medicine medicine T-VEC talimogene laherparepvec Survival rate business.industry food and beverages intralesional medicine.disease Oncolytic virus talimogene laherparepvec oncolytic 030220 oncology & carcinogenesis Talimogene laherparepvec business medicine.drug |
| Zdroj: | JAAD Case Reports |
| ISSN: | 2352-5126 |
| Popis: | Merkel cell carcinoma (MCC) is a rare cutaneous neuroendocrine malignancy that is highly aggressive and considered incurable upon distant metastasis. The incidence rate in the United States has significantly increased in the last 30 years and is estimated to be 0.79 per 100,000.1 The prognosis for advanced MCC is poor, with a 5-year overall survival rate of 0% to 18%.2 Although MCC is chemotherapy sensitive, responses are not durable, and most patients with advanced MCC succumb to the disease. Avelumab and pembrolizumab are the only treatments approved by the US Food and Drug Administration for patients with MCC thus far. A phase II study found a 1-year progression-free survival rate of 30% compared with 0% with chemotherapy.3, 4 Talimogene laherparepvec (T-VEC) is a modified oncolytic herpes simplex virus that replicates in tumor cells and expresses granulocyte-macrophage colony-stimulating factor, promoting local and systemic antitumor response. T-VEC treatment was approved by the US Food and Drug Administration for treatment of advanced melanoma. In a phase III study, intralesional T-VEC injection had superior durable and overall response rates compared with subcutaneous granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.5 However, the clinical benefit of T-VEC in patients with advanced MCC is not known. Here we report on a patient with surgically incurable, recurrent MCC who had a complete response to intralesional T-VEC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|